SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-051234
Filing Date
2024-05-01
Accepted
2024-05-01 16:01:36
Documents
83
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q srpt-20240331.htm   iXBRL 10-Q 2698534
2 EX-10.2 srpt-ex10_2.htm EX-10.2 87805
3 EX-10.3 srpt-ex10_3.htm EX-10.3 70097
4 EX-31.1 srpt-ex31_1.htm EX-31.1 11699
5 EX-31.2 srpt-ex31_2.htm EX-31.2 11750
6 EX-32.1 srpt-ex32_1.htm EX-32.1 7988
7 EX-32.2 srpt-ex32_2.htm EX-32.2 7917
  Complete submission text file 0000950170-24-051234.txt   10396544

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20240331.xsd EX-101.SCH 1413643
87 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20240331_htm.xml XML 1854653
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

IRS No.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14895 | Film No.: 24902839
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)